Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: result... by Tanaka, Y, Weinblatt, M, Taylor, PC, Fleischmann, R, Ishizuka, T, Tanaka, M, Takita, Y, Schlichting, D, Takeuchi, T

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo by Taylor, P, Fleischmann, R, Perkins, E, Lisse, J, Zhu, B, Gaich, C, Zhang, X, Schlichting, D, Dickson, C, Takeuchi, T

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis by Kremer, J, Genovese, M, Keystone, E, Taylor, P, Zuckerman, S, Ruotolo, G, Schlichting, D, Crotzer, V, Nantz, E, Beattie, S, Macias, W

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirhe... by Genovese, M, Keystone, E, Taylor, P, Drescher, E, Berclaz, P, Lee, C, Schlichting, D, Beattie, S, Fidelus-Gort, R, Luchi, M, Macias, W

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS by Taylor, P, Genovese, M, Keystone, E, Drescher, E, Berclaz, P, Lee, C, Fidelus-Gort, R, Schlichting, D, Beattie, S, Luchi, M, Macias, W

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. by Keystone, E, Taylor, P, Drescher, E, Schlichting, D, Beattie, S, Berclaz, P, Lee, C, Fidelus-Gort, R, Luchi, M, Rooney, T, Macias, W, Genovese, M

Baricitinib 4mg and 2mg once-daily reduced pain in both patients who were opioid users and non-users in active rheumatoid arthritis: a post-hoc analysis of phase 3 trials by Pope, J, Lee, Y, Curtis, J, Mo, D, Rooney, T, Xie, L, Dickson, C, Schlichting, D, Quebe, A, Cardoso, A, Simon, L, Taylor, P

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modify... by Peterfy, C, Emery, P, Genovese, M, Keystone, E, Taylor, P, Berclaz, P, DiCarlo, J, Lee, C, Schlichting, D, Beattie, S, Luchi, M, Macias, W

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis by Tanaka, Y, McInnes, I, Taylor, P, Byers, N, Chen, L, de Bono, S, Issa, M, Macias, W, Rogai, V, Rooney, T, Schlichting, D, Zuckerman, S, Emery, P

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study by Emery, P, Taylor, P, Weinblatt, M, Tanaka, Y, Keystone, E, Dow, E, Higgs, R, Macias, W, Rocha, G, Rooney, T, Schlichting, D, Zuckerman, S, McInnes, I

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial by Taylor, P, Lee, Y, Fleischmann, R, Takeuchi, T, Perkins, E, Fautrel, B, Zhu, B, Quebe, A, Gaich, C, Zhang, X, Dickson, C, Schlichting, D, Patel, H, Durand, F, Emery, P

Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’... by Taylor, P, Keystone, E, Van Der Heijde, D, Tanaka, Y, Ishii, T, Emoto, K, Yang, L, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, De Bono, S, Weinblatt, M, Combe, B

Baricitinib versus placebo or adalimumab in rheumatoid arthritis by Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y